Annovis Bio Inc Stock Price, News & Analysis

Annovis Bio (NYSE: ANVS) announced its participation in the 13th Alzheimer's & Parkinson's Drug Development Summit in Boston, MA, from March 18-20, 2025. The company's Founder and CEO, Maria Maccecchini, Ph.D., will present Phase III buntanetap data and participate in a panel discussion on March 19.

The presentation at 3:30pm EST will focus on buntanetap's clinical trial results and advocate for a holistic approach to treating neurodegenerative diseases. At 4:30pm EST, Dr. Maccecchini will join a panel exploring opportunities in alpha-synuclein and future developments in Parkinson's drug development.

The company emphasizes the need to move beyond single-protein targeting approaches, highlighting their strategy of addressing multiple neurotoxic proteins in treating conditions like Alzheimer's and Parkinson's disease.

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, announces a live webcast Patients' Forum scheduled for February 27, 2025, at 4:30 PM EST. CEO Maria Maccecchini, Ph.D., will lead the session, addressing questions from patients, caregivers, and families.

The forum will provide updates on several key areas including:

• Ongoing Phase 3 Alzheimer's disease trial
• Plans for Phase 3 Parkinson's disease study
• Open Label Extension studies
• Patient communication strategies

The event will feature a presentation of recent achievements followed by a Q&A session. Participants can submit questions in advance to clinicaltrials@annovisbio.com. While open to all, the forum is specifically designed for patients, families, and caregivers, demonstrating Annovis's commitment to transparency and patient-centered communication.

Annovis Bio (NYSE: ANVS) has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. CEO Maria Maccecchini, Ph.D., will deliver a presentation on February 11, 2025, from 12:40 to 1:10 p.m. ET through the conference's virtual platform.

The presentation will focus on the company's recent developments, particularly highlighting progress in their pivotal Phase 3 trial for early Alzheimer's disease. Dr. Maccecchini will also discuss strategic initiatives regarding a New Drug Application (NDA) for buntanetap, which is being developed as both a symptomatic and potentially disease-modifying treatment.

The conference is a significant industry event that connects leading healthcare and life sciences companies with investors, offering a platform for executives to share insights on industry trends, innovations, and investment opportunities.

Annovis Bio (NYSE: ANVS) has initiated its pivotal Phase 3 study of buntanetap for early Alzheimer's disease (AD) with the enrollment of the first two patients. The randomized, placebo-controlled, double-blind study will evaluate the drug's safety and efficacy over 18 months, divided into a 6-month assessment of symptomatic effects and a 12-month evaluation of disease-modifying effects.

The study follows positive Phase 2/3 trial results showing significant cognitive improvement in early AD patients with no safety concerns. The company recently raised $21 million through a public offering to fund the initial 6-month portion, with the remaining 12-month phase expected to be funded through warrant exercises.

The trial will enroll over 750 participants across approximately 100 U.S. sites, with primary outcomes measured using the ADAS-Cog13 subscale for cognition and ADCS-iADL scale for functional ability. The first two sites have begun recruiting in Winter Park, FL and Tom's River, NJ.

Annovis Bio (NYSE: ANVS) has completed its previously announced public offering, raising $21 million in gross proceeds. The offering consisted of 5,250,000 shares of common stock and warrants to purchase an additional 5,250,000 shares at a combined price of $4.00 per share and associated warrant. The warrants are immediately exercisable at $5.00 per share for five years.

The company plans to use the net proceeds primarily to fund the Phase 3 clinical development of Buntanetap for Alzheimer's disease, along with working capital and general corporate purposes. ThinkEquity served as the sole book-running manager for the offering, which was conducted under a shelf registration statement on Form S-3.

Annovis Bio (NYSE: ANVS) has announced the pricing of a public offering consisting of 5,250,000 shares of common stock and warrants to purchase an equal number of shares at a combined price of $4.00 per share. The warrants will have an exercise price of $5.00 per share, exercisable immediately for five years after issuance.

The offering is expected to raise $21 million in gross proceeds before deducting underwriting discounts and expenses. The company plans to use the net proceeds for working capital and general corporate purposes, including the continued clinical development of their lead compound, Buntanetap. ThinkEquity is serving as the sole book-running manager for the offering, which is expected to close on February 4, 2025.

Annovis Bio (NYSE: ANVS) has announced plans for an underwritten public offering of common stock and warrants. ThinkEquity will serve as the sole book-running manager, with a 45-day option to purchase up to an additional 15% of shares and/or warrants to cover over-allotments.

The company intends to use the proceeds primarily for working capital and general corporate purposes, including the continued clinical development of their lead compound, Buntanetap. The offering will be made through a shelf registration statement on Form S-3 filed with the SEC.

Annovis Bio is a late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease. The completion and terms of the offering are subject to market conditions.

Annovis Bio (NYSE: ANVS) has been granted a U.S. patent for using buntanetap in the treatment and prevention of acute brain or nerve injuries. The patent, issued on January 2, 2025, extends the company's global protection, as similar patents have already been granted in the EU, Japan, and other regions worldwide.

The patent is based on buntanetap's capability to reduce neurotoxicity and mitigate neurodegenerative processes, making it potentially applicable to conditions such as stroke, ischemia, traumatic brain injury, micro infarcts, and other acute injuries. This expands the potential applications of buntanetap beyond its primary indications of Alzheimer's and Parkinson's diseases.

Annovis Bio (NYSE: ANVS) announced that the FDA has accepted an updated protocol for its pivotal Phase 3 Alzheimer's Disease (AD) study, set to begin in January 2025. The revised protocol integrates two separate trials into a single 6/18-month trial. The original design included a 6-month symptomatic study and an 18-month disease-modifying study. Now, the consolidated protocol features a 6-month data readout focused on symptomatic effects, followed by an additional 12-month assessment for disease-modifying potential.

In October 2024, the FDA granted clearance for Annovis to proceed based on Phase 2/3 data showing cognitive improvement in early-stage AD patients. According to Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, this streamlined approach will accelerate the development timeline while maintaining scientific rigor. The 6-month symptomatic data could potentially support a New Drug Application (NDA) filing, continuing seamlessly to evaluate long-term outcomes.

This development marks a significant step in advancing buntanetap as a novel treatment for AD, bringing the company closer to delivering new therapeutic options for patients.